Cargando…
Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
Autores principales: | del Carmen Asensio Lopez, Maria, Lax, Antonio, Hernandez Vicente, Alvaro, Saura Guillen, Elena, Hernandez-Martinez, Antonio, Fernandez del Palacio, Maria Josefa, Bayes-Genis, Antoni, Pascual Figal, Domingo A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547718/ https://www.ncbi.nlm.nih.gov/pubmed/33037250 http://dx.doi.org/10.1038/s41598-020-73065-5 |
Ejemplares similares
-
Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
por: Asensio Lopez, Maria del Carmen, et al.
Publicado: (2020) -
The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI
por: Asensio-Lopez, Maria Carmen, et al.
Publicado: (2021) -
Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019) -
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
por: Lax, Antonio, et al.
Publicado: (2023) -
Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers
por: Mencacci, Niccolò E., et al.
Publicado: (2014)